Stock Ratings / Health Care / LYEL / forecast

LRMR (50) RCKT (31) GLSI (41) BIOA (44) ⌘ Pro Terminal →

Lyell Immunopharma Inc. (LYEL) 12-Month Stock Forecast & Price Target Cone

$11.31 +3.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Lyell Immunopharma Inc. (LYEL) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $277.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LYEL)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your LYEL Position Size: $10,000

Shares at $11.31: 884.2 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $8.03

$7,100

$-2,900 (-29.0%)

12M Consensus BaseTarget $10.29

$9,098

$-902 (-9.0%)

12M Bull Case BreakoutTarget $47.25

$41,777

+$31,777 (+317.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$11	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$44	69%	B
JP MorganUS Large-Cap Research	SELL	$9	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LYEL)

✓Walkthrough of LYEL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LYEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.68%📐 HORIZONTAL RANGE

2026-10-30O $11.26H $11.43L $10.79C $11.31VOL 113.3K

RES: $17.74SUP: $6.11SMA50: $11.02SMA200: $16.87

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LYEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LYEL Butterfly Map → + Track LYEL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -41.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LYEL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LYEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LYEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LYEL)

Health Care Rank #710 of 1016 ⚔️ LRMR vs LYEL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LYEL vs. LRMR, RCKT, GLSI, BIOA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lyell Immunopharma Inc. (LYEL) ranks #710 by composite RQD confidence (38/100, grade D-) and #531 by equity capitalization ($277.0M). Within this direct 5-issuer industry benchmark cohort, LYEL leads on earnings valuation at N/A trailing P/E, while LYEL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LRMR currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with LYEL at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LYEL ACTIVE Lyell Immunopharma Inc.	D-	38/100	—	—	-35.0%	+3.43%	$277.0M	Benchmark Subject
LRMR Larimar Therapeutics Inc.	D	50/100	—	—	-35.0%	+5.12%	$277.4M	/lrmr-vs-lyel →
RCKT Rocket Pharmaceuticals Inc.	E	31/100	—	—	-35.0%	-1.55%	$278.8M	/rckt-vs-lyel →
GLSI Greenwich LifeSciences Inc.	D-	41/100	—	—	-35.0%	+3.77%	$278.9M	/glsi-vs-lyel →
BIOA BioAge Labs Inc.	D	44/100	—	—	-35.0%	0.00%	$272.6M	/bioa-vs-lyel →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001806952

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lyell Immunopharma Inc. (LYEL) reported GAAP revenue of $36.0K (-41.0% vs. FY2024 revenue of $61.0K , and -72.3% cumulative change since FY2023) , GAAP net income of -$274.4M, operating cash flow of -$150.0M, and free cash flow of -$150.8M (+7.4% YoY). On the balance sheet, LYEL closed FY2025 with $340.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$36.0K	-$274.4M	-$150.0M	-$150.8M	$340.1M	—
FY2024 (FY)	2024-12-31	$61.0K	-$343.0M	-$162.4M	-$162.9M	$490.9M	—
FY2023 (FY)	2023-12-31	$130.0K	-$234.6M	-$163.7M	-$163.7M	—	—

3. LYEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LYEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lyell Immunopharma Inc. (NASDAQ: LYEL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $11.31 (+3.43% 1D, market cap $277.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LYEL ranks #710 in composite RQD confidence.

How does LYEL compare to LRMR and RCKT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LYEL carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LRMR (Larimar Therapeutics Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $277.4M) and RCKT (Rocket Pharmaceuticals Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $278.8M). Among the 5-stock peer group, LYEL leads on earnings multiple (N/A) while LYEL leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LYEL?

Per LYEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001806952), Lyell Immunopharma Inc. generated $36.0K in revenue (-41.0% YoY), -$274.4M in net income, and -$150.8M in free cash flow against $340.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LYEL trading relative to its 50-day, 200-day, and 52-week technical levels?

LYEL last traded at $11.31 (+3.43% on volume of 149,226 shares), positioning the stock +2.63% above its 50-day simple moving average ($11.02) and -32.96% below its 200-day simple moving average ($16.87). Across its 52-week range of $7.20 to $45.00, LYEL sits at the 10.9% percentile with a 14-day RSI of 61.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($9.90 to $12.72).

LYEL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is LYEL's 12-month stock price target?

Lyell Immunopharma Inc. (LYEL) carries a 12-month consensus base price target of $10.29 (-9% from $11.31), with a bull-case target of $47.25 and a bear-case floor of $8.03.

Is LYEL stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates LYEL D- (Sell — SELL) with an RQD Confidence score of 38/100.

Direct Sub-Reports: LYEL RQD Cockpit LYEL 12M Forecast LYEL Earnings & Move LYEL Dividends & DRIP LYEL Insiders & 13F LYEL Whale Options LYEL Profit Sankey LYEL News & Why